Abstract
Infection with hepatitis A and hepatitis B viruses is a major public health problem. The development and availability of safe and immunogenic vaccines, which have been shown to be highly effective, constitute a major advance in preventive medicine. Several current issues of practical importance are reviewed below.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Carman WF, Zanetti AR, Karayiannis P, Water J, Manzillo G, Tanzi E, Zuckerman AJ, Thomas HC (1990) Vaccine-induced escape mutant of hepatitis B virus. Lancet 336:325–329
Harrison TJ, Zuckerman AJ (1992) Variants of hepatitis B virus. Vox Sang 63:161–167
Lemon SM, Stapleton JT (1997) Prevention of hepatitis A. In: Zuckerman AJ, Thomas HC (eds) Viral hepatitis: scientific basis and clinical management, 2nd edn. Churchill Livingstone, Edinburgh (in press)
McDermott AR, Zuckerman JN, Sabin CA, Marsh SGE, Madrigal JA (1997) The contribution of the human leukocyte antigens in the antibody response to hepatitis B vaccination. Tissue Antigens 50:8–14
Oon C-J, Lim G-K, Zhao Y, Goh K-T, Tan K-L, Yo S-L, Hopes E, Harrison TJ, Zuckerman AJ (1995) Molecular epidemiology of hepatitis B virus vaccine variants in Singapore. Vaccine 13:699–702
Oon C-J, Tan K-L, Harrison T, Zuckerman AJ (1996) Natural history of hepatitis B surface antigen mutants in children. Lancet 348:1524
Tedder RS, Zuckerman MA, Brink N (1993) Hepatitis B vaccination: non-responders must be detected. Lancet 307:732
Vandamme P, Thoelen S, Cramm M, de Groote K, Safary A, Meheus A (1994) Inactivated hepatitis A vaccine: reactogenicity, immunogenicity and long-term antibody persistence. J Med Virol 44:446–451
Vidor E, Fritzell B, Plotkin S (1996) Clinical development of a new inactivated hepatitis A vaccine. Infection 24:447–458
Westmoreland D, Player V, Heap DC, Hammond A (1990) Immunization against hepatitis B — what can we expect? Epidemiol Infect 104:499–509
WHO (1983) Prevention of liver cancer. WHO Tech Rep Ser 691
Wiedermann G, Ambrosch F, André FE, d’Hondt E, Delem AD, Safary A (1992) Persistence of vaccine-induced antibody to hepatitis A virus. Vaccine 10:S129–S131
Zanetti AR, Tanzi E, Manzillo G, Maio G, Sbreglia C, Caporaso N, Thomas H, Zuckerman AJ (1988) Hepatitis B variant in Europe. Lancet 2:1132–1133
Zuckerman AJ (ed) (1996) Prevention of hepatitis B in the newborn, children and adolescents. Royal College of Physicians, London
Zuckerman JN (1996) Nonresponse to hepatitis B vaccines and the kinetics of anti-HBs production. J Med Virol 56:283–288
Zuckerman JN, Sabin C, Craig FM, Williams A, Zuckerman AJ (1997) Immune response to a new hepatitis B vaccine in health care workers who had not responded to standard vaccine: randomised double blind dose-response study. Br Med J314:329–333
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Zuckerman, J.N., Zuckerman, A.J. (1998). Current Issues in Immunisation Against Hepatitis A and B. In: Eibl, M.M., Huber, C., Peter, H.H., Wahn, U. (eds) Symposium in Immunology VII. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-80466-3_2
Download citation
DOI: https://doi.org/10.1007/978-3-642-80466-3_2
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-63360-0
Online ISBN: 978-3-642-80466-3
eBook Packages: Springer Book Archive